Endocrinology

Top Story

Addition of Farxiga to insulin, liraglutide improves glycemia in type 1 diabetes

Addition of Farxiga to insulin, liraglutide improves glycemia in type 1 diabetes
May 26, 2016

ORLANDO, Fla. — Patients with type 1 diabetes treated with insulin and liraglutide with the addition of Farxiga have significantly improvements in glycemia.

Farxiga (dapagliflozin, Astra Zeneca) is an SGLT2 inhibitor that blocks the reabsorption of glucose by the kidney, increases glucose excretion and lowers blood glucose levels.

Meeting News Coverage

Liraglutide as adjunct to insulin reduces HbA1c, BMI

May 26, 2016
ORLANDO, Fla. — Patients with type 1 diabetes treated with liraglutide as an adjunct to insulin had significantly reduced HbA1c and BMI, according to findings…
Meeting News Coverage

AACE opening ceremony marks 25 years of growth, achievements

May 26, 2016
ORLANDO, Fla. — It was 25 years ago when “a handful of dreamers” organized what would become the first American Association of Clinical…
Meeting News Coverage

ATMOSPHERE: Aliskiren fails to benefit patients with HF, diabetes vs. enalapril

May 26, 2016
In patients with diabetes and HF, the direct renin inhibitor aliskiren did not significantly improve outcomes compared with the ACE inhibitor enalapril, according to new…
Meeting News Coverage

New agents on the horizon appear promising for managing osteoporosis

May 26, 2016
ORLANDO, Fla. — Three new nonbisphosphonate agents for the treatment of osteoporosis are anticipated, according to a speaker here. Rachel Pessah-Pollack, MD
More News Headlines »
CME

Obesity Consults® ObesityForum® 2015 Highlights

This activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc. and Novo Nordisk, Inc.

Obesity has increased dramatically in the past 20 years and is considered a health care epidemic in the United States…
More »
Video
Meeting News Coverage

VIDEO: Human induced pluripotent stem cells may help study of osteoporosis, rare genetic diseases

April 8, 2016
More »
Featured
Highlights from AACE

Highlights from AACE

CME

Avoiding “Loss of Chance”… Improving the Screening, Treatment, and Referral of Patients with Diabetic Retinopathy

This activity is supported by an educational grant from Genentech, Inc.

Despite a number of effective treatment options, diabetic eye disease is a leading cause of vision loss in the United…
More »
Current Issues
View the Current Issues